Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹100 Cr
P/E Ratio
25.37
P/B Ratio
1.89
Industry P/E
37.87
Debt to Equity
0.11
ROE
11.72 %
ROCE
13.61 %
Div. Yield
0.42 %
Book Value
440.73
EPS
32.88
CFO
₹45.08 Cr
EBITDA
₹69.42 Cr
Net Profit
₹38.15 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Mercury Lab
| -6.93 | 1.82 | -3.91 | -6.72 | 19.75 | 25.53 | 35.04 |
|
BSE Healthcare
| -6.54 | 1.91 | 4.84 | 19.10 | 20.06 | 22.35 | 10.14 |
|
BSE Small Cap
| -11.96 | 3.43 | 1.57 | 2.12 | 18.79 | 34.74 | 16.10 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Mercury Lab
| -21.76 | 32.17 | 11.07 | 42.95 | 86.36 | -25.83 | -19.78 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 421.25 | 6,849.42 | 24.96 | 12.5 | |
| 5,111.50 | 8,500.54 | 35.93 | 43.77 | |
| 664.45 | 6,499.67 | 73.62 | 4.01 | |
| 651.90 | 6,014.08 | 22.31 | 12.68 |
No Review & Analysis are available.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
Incorporated
1982
Chairman
Bharat Mehta
Managing Director
Rajendra R Shah
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Mercury Laboratories Ltd stood at ₹ 69 Cr as on 31-Dec-24
The share price of Mercury Laboratories Ltd is ₹833.95 (BSE) as of 29-Apr-2025 IST. Mercury Laboratories Ltd has given a return of 19.75% in the last 3 years.
Mercury Laboratories Ltd has a market capitalisation of ₹ 100 Cr as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Mercury Laboratories Ltd is 1.89 times as on 29-Apr-2025, a 63% discount to its peers’ median range of 5.06 times.
The P/E ratio of Mercury Laboratories Ltd is 25.37 times as on 29-Apr-2025, a 33% discount to its peers’ median range of 37.87 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Mercury Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Mercury Laboratories Ltd.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
The prominent promoters of Mercury Laboratories Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Shah Dilip Ramanlal HUF |
25.88%
|
|
Shah Rajendra Ramanlal HUF |
17.42%
|
|
Janki Rajendra Shah |
8.67%
|
|
Rajendra Ramanlal Shah |
7.14%
|
|
Dilip Ramanlal Shah |
7.07%
|
The chairman of the company is Bharat Mehta, and the managing director is Rajendra R Shah.
There is no promoter pledging in Mercury Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,423
|
|
|
6,920
|
|
|
6,675
|
|
|
6,029
|
| Mercury Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
7.69
|
|
Operating margin(%)
|
6.52
|
|
Net Margin(%)
|
5.4
|
|
Dividend yield(%)
|
0.42
|
Yes, TTM profit after tax of Mercury Laboratories Ltd was ₹4 Cr.
₹18.45
(
